Sareum Holdings PLC Sareum enhances SDC-1801 patent protection (2490S)
November 03 2023 - 2:05AM
UK Regulatory
TIDMSAR
RNS Number : 2490S
Sareum Holdings PLC
02 November 2023
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum strengthens patent protection for lead programme
SDC-1801
- Notice of Allowance from Japan Patent Office received
Cambridge, UK , 3 November 2023 - Sareum Holdings plc (AIM:
SAR), a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer, today announces that
the Japan Patent Office has issued a Notice of Allowance for a
patent relating to SDC-1801, the Company's lead TYK2/JAK1 kinase
inhibitor.
The newly approved Japanese patent, Special Application
2021-543577, safeguards SDC-1801 and its medical applications in
treating inflammatory or immune disorders. This follows the earlier
approval by the China National Intellectual Property Administration
(CNIPA), which issued patent number CN113056456B for the same
protections earlier this year. Patent applications in Europe
(EP3864009), the US (US2021387981), and other territories are still
under review.
The Company expects that the patent will be granted in the near
future, subject to certain formalities being completed.
Dr John Reader, Sareum's Chief Scientific Officer, commented:
"The recent Notice of Allowance from the Japan Patent Office
bolsters our growing confidence in SDC-1801, our lead TYK2/JAK1
kinase inhibitor. Our Phase 1a clinical trial in Australia is
progressing well, and this latest patent recognition in Japan
supports our intellectual property around this programme."
Further information on our patents can be found on our website
at: https://sareum.com/patents/
-Ends-
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497700
Lauren Williams, Head of Investor Relations ir@sareum.co.uk
Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman 020 7409 3494
Peel Hunt LLP (Joint Corporate Broker)
James Steel / Patrick Birkholm 020 7418 8900
Hybridan LLP (Joint Corporate Broker)
Claire Noyce 020 3764 2341
ICR Consilium (Financial PR)
Jessica Hodgson / Davide Salvi / Stella
Lempidaki 020 3709 5700
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology
company developing next generation kinase inhibitors for autoimmune
disease and cancer.
The Company is focused on developing next generation small
molecules which modify the activity of the JAK kinase family and
have best-in-class potential. Its lead candidate, SDC-1801,
simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential
treatment for a range of autoimmune diseases and has entered Phase
1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1
inhibitor which it originally developed in collaboration with
several Cancer Research UK-related organisations. SRA737 has shown
promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a
potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on
the AIM market of the London Stock Exchange, trading under the
ticker SAR. For further information, please visit the Company's
website at www.sareum.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUURBROUUARAA
(END) Dow Jones Newswires
November 03, 2023 03:05 ET (07:05 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From May 2024 to Jun 2024
Sareum (LSE:SAR)
Historical Stock Chart
From Jun 2023 to Jun 2024